Pharming Group N.V.
NASDAQ:PHAR · NASDAQ Global Market
+$0.28 today
Vol 0.00M · Avg 0.01M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
1.0%
avg -41.3%
ROIC
1.0%
avg -52.7%
ROA
0.6%
avg -2.4%
Analysis
ROIC is currently the strongest return metric at 1.0% versus its period average of -52.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Fabrice Chouraqui | Chief Executive Officer & Executive Director | $1.84M | — | — | — | — |
Bruno L. Giannetti | Consultant | — | — | 74 | — | — |
Magnus Hansson | Medical Director | — | — | 50 | — | — |
Ines Bernal | Chief People Officer | — | — | — | — | — |
Michael Levitan | Vice President of Investor Relations & Corporate Communications | — | — | — | — | — |
Ruud Van Outersterp | Chief Legal & Compliance Officer and Company Secretary | — | — | 62 | — | — |
Leverne Marsh | Chief Commercial Officer | — | — | — | — | — |
Mireille Sanders | Chief Operations Officer | — | — | 58 | — | — |
Alexander Breidenbach | Chief Business Officer | — | — | 63 | — | — |
Anurag Relan | Chief Medical Officer | — | — | 54 | — | — |
Kenneth Lynard EMBA | Chief Financial Officer | — | — | 58 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -8.3% | +32.3% (15yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -8.3% over three years. Forward estimates point to Revenue at +32.3% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.52B
Septerna, Inc.
NASDAQ:SEPN
$1.58B
Mind Medicine (MindMed) Inc.
MNMD
$1.56B
Fortrea Holdings Inc.
NASDAQ:FTRE
$1.44B
Palvella Therapeutics, Inc.
NASDAQ:PVLA
$1.32B
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
$1.27B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.13B
Arbutus Biopharma Corporation
NASDAQ:ABUS
$884.97M
Kura Oncology, Inc.
NASDAQ:KURA
$857.56M
ProKidney Corp.
NASDAQ:PROK
$261.29M
Who manages PHAR?
Pharming Group N.V. (PHAR) lists 11 active executives. The top listed executive is Bruno L. Giannetti, Consultant.
Are PHAR insiders buying or selling?
Recent insider activity shows net buying of $3,400.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.